The present invention is made of intestinal microorganisms isolated from the digestive tract of a person that can replace fecal enzymes used for the toxicity evaluation or physiological activity evaluation of drugs / food components, etc. in vitro in place of the digestive tract metabolic system. Intestinal microbial enzyme mixture (intestinal microbial enzyme mixture, enzyme mix) and a method for producing the same, p-nitrophenyl-β-D-glucolonide, p-nitrophenyl-β-D-xylpy When enteric microbial enzyme complexes having substrate activity against lanoxide, nitrophenyl-α-L-rampranopyranoside and p-nitrophenyl-β-D-glucopyranoside were applied as metabolic activity to the Ames test In addition, since it was confirmed that the number of reverse mutations increased significantly when applying the picalase, which has been previously used as a metabolic system in the digestive tract, the intestinal microbial complex of the present invention was applied to the metabolic system in the digestive tract. In vitro Chromosomal Aberration Assay, In vitro Micronucleus Assay, Mouse Lymphoma Assay (MLA), In vitro Mammalian Cells In vitro Mammalian Cell Micronucleus Test, Comet Assay, Mammalian Spermatogonial Chromosome Aberration Assay, SOS Chromotest, and Bacterial Reverse Test Evaluation of the donor ability (mutation test, Ames test) method, or physiological activity, evaluation of superoxide dismutase (SOD) -like activity, evaluation of antioxidant activity through nitrite scavenging ability and evaluation of anti-allergic effect Applicable to본 발명은 소화관내 대사계를 대신하여 시험관 내에서 의약품/식품성분 등의 독성 평가 또는 생리활성 평가를 위해 사용되는 분변 효소액(Fecalase)을 대체할 수 있는 사람의 소화관내에서 분리한 장내 미생물로 제조한 장내 미생물 효소복합체(intestinal microbial enzyme mixture, enzyme mix)및 이의 제조방법에 관한 것으로, p-나이트로페닐-β-D-글루커로니드, p-나이트로페닐-β-D-자일로파이라노시드, 나이트로페닐-α-L-람노파이라노시드 및 p-나이트로페닐-β-D-글루코파이라노시드에 대해 기질 활성을 갖는 장내 미생물 효소복합체를 에임즈 시험에 대사 활성계로 적용하였을 때, 기존에 소화관내 대사계로 사용되어 왔던 피칼라제를 적용했을 때와 유의적으로 복귀돌연변이원 수가 증가함을 확인하였으므로, 본 발명의 장내 미생물 복합체를 소화관내 대사계에 대한 대사 활성
